Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab dose-ranging MRI study in relapsing-remitting multiple sclerosis
2011-002333-19Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by GSK. Primary endpoint: Cumulative number of new T1 gadolinium-enhancing brain lesions at Week 12. Started Sep 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2011-002333-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002333-19.